{"listing":{"listing_type":"company","name":"OMass Therapeutics","slug":"omass-therapeutics","tagline":"Oxford spin-out discovering small-molecule medicines with native mass spectrometry","description":"OMass Therapeutics is a UK biotech founded in 2016 as a spin-out from Professor Dame Carol Robinson's lab at the University of Oxford. Its OdyssION discovery platform combines native mass spectrometry, proprietary biochemistry and custom chemistry to study drug targets such as solute carriers and GPCRs within their native ecosystems. Its lead programme OMS1620, an MC2 receptor antagonist, is heading through Phase 2 development in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with an SLC15A4 inhibitor for lupus following. In October 2026 it announced an oversubscribed €275 million (£230 million) Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings. Ros Deegan is CEO.","url":"https://www.omass.com/","is_stealth":false,"normalized_domain":"omass.com","normalized_url_key":"omass.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://www.omass.com/app/uploads/2021/10/favicon-300x300.png","links":[{"label":"X / Twitter","url":"https://x.com/omasstx","platform":"x"},{"label":"LinkedIn","url":"https://www.linkedin.com/company/omass-therapeutics","platform":"linkedin"},{"label":"EU-Startups: €275M Series C","url":"https://www.eu-startups.com/2026/10/oxford-spin-out-omass-therapeutics-lands-e275-million-to-bring-novel-small-molecule-therapies-closer-to-patients/","platform":"other"}],"entry_points":[{"kind":"homepage","url":"https://www.omass.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://www.omass.com/news/","audience":"human","label":"News","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://www.omass.com/pipeline/","audience":"human","label":"Pipeline","primary":false,"listed_by":"community","on_listing_domain":true},{"kind":"other","url":"https://www.omass.com/team/","audience":"human","label":"Team","primary":false,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.omass.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[{"name":"Carol Robinson","role":"Scientific founder","person_slug":"carol-robinson-07yzbvsji0wu7","bio":null,"location":null,"links":[]}],"media":{"logo_asset_id":"b9a04760-1747-4c4e-8190-121f6037aa47"},"categories":["Biotechnology","Drug Discovery","Life Sciences","Healthcare"],"stage":"series-b+","founded_year":2016,"location":"Oxford, United Kingdom","pricing":null,"twitter":"https://x.com/omasstx","github":null,"linkedin":"https://www.linkedin.com/company/omass-therapeutics","contact_email":null,"added_at":"2026-10-17T04:25:16.920Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-17T04:25:16.920Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"life-sciences","name":"Life Sciences","note":null,"profile_url":"/industries/life-sciences"}]}}